Update on proposed Share Reorganisation
01 September 2023
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces an update with regards its proposed Share Reorganisation as notified in the Company's Notice of Annual General Meeting, which was posted to shareholders on 11 August 2023.
Proposed Share Reorganisation
Having consulted with a number of shareholders post the announcement of 31 August, the board has decided not to proceed with the proposed Share Reorganisation and associated consolidation of the Ordinary Shares. The board will withdraw Resolution 8 set out in the Notice of AGM with regards the Share Reorganisation.
Accordingly, the issued share capital of the Company will remain unchanged at 237,685,180 ordinary shares of 4 pence each and 123,245,615 deferred shares of 0.9 pence each.
The Company remains well funded and the Directors reiterate that they have no need or intention to raise funds at this time.
Omega Diagnostics Group PLC
Jag Grewal, Chief Executive Officer
via Walbrook PR
Tel: 020 7220 0500
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Walbrook PR Limited
Tel: 020 7933 8780 or [email protected]
Paul McManus / Lianne Applegarth
Mob: 07980 541 893 / 07584 391 303
Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.